| Literature DB >> 28397162 |
Ming Wu1, Peter Pokreisz1,2, Melissa Swinnen1, Ellen Caluwe1, Hilde Gillijns1, Nina Vanden Driessche1, Andrea Casazza2, Erik Verbeken3, Desire Collen1,2, Stefan Janssens4.
Abstract
Angiogenic growth factor therapy for ischemic cardiovascular disease carries a risk of stimulating atherosclerotic plaque growth. We evaluated risk benefit ratio of sustained administration of recombinant human placental growth factor (rhPlGF)-2 in mice with advanced atherosclerosis and chronic ischemic cardiomyopathy. We maintained apolipoprotein E-deficient mice on a high cholesterol diet and induced myocardial infarction by transient ligation at 4 weeks. At 8 weeks, we assessed left ventricular (LV) function and randomized mice to receive rhPlGF-2 or vehicle (VEH) subcutaneously for 28 days. Administration of rhPlGF-2 significantly increased PlGF plasma levels without adverse hemodynamic or systemic inflammatory effects. RhPlGF-2 did not increase plaque area, composition, or vulnerability in the aortic arch. RhPlGF-2 significantly improved contractile function and reduced LV end-systolic and end-diastolic volume indices with a concomitant increase in capillary and arteriolar density in ischemic myocardium. RhPlGF-2 may represent a promising therapeutic strategy in chronic ischemic cardiomyopathy.Entities:
Keywords: Angiogenesis; Atherosclerosis; Growth factor; Ischemic cardiomyopathy; Placental growth factor-2
Mesh：
Substances：
Year: 2017 PMID： 28397162 DOI： 10.1007/s12265-017-9742-4
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN： 1937-5387 Impact factor: 4.132